These findings resonate with the effectiveness of gonadorelin (GnRH) prophylaxis in preventing AIP, for which an audit reported that in 50% of patients (11/22) who considered the treatment ineffective and intolerable, the main complaint was estrogen deficiency (Schulenburg-Brand et al., 2017). This evidence concerns the gene GNRH1 and autoimmune pancreatitis.